Engflag

Aspi-Cor

Quick links to important sections

Aspi-Cor

Aspi-Cor_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aspi-Cor

Quick Facts

Property Description
Active Ingredient Acetylsalicylic acid (ASA)
Form Tablets (often enteric-coated)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Antiplatelet Agent
Common Use Focus Cardiovascular support and minor pain relief
Origin Synthetic Compound

What is Aspi-Cor, and What is its Composition?

Aspi-Cor is a commercial preparation based on the well-established synthetic compound Acetylsalicylic acid (ASA), known universally as Aspirin. It is defined as a single active ingredient product (monotherapy), focusing all its effects on the properties of ASA. Pharmacologically, it is primarily categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID), but its distinguishing therapeutic characteristic is its function as an Antiplatelet agent (platelet aggregation inhibitor). This dual classification is central to understanding its roles, which have been clinically recognized for decades of therapeutic use in cardiovascular medicine.

Aspi-Cor: Understanding the Dosage Form

Aspi-Cor is supplied as solid dosage forms, specifically tablets, intended solely for oral administration (swallowing). The tablets frequently utilize specialized manufacturing techniques, often featuring a film-coating or, more commonly, an enteric-coating. The enteric-coated tablet form is designed to resist the acidic environment of the stomach, delaying the release of the Acetylsalicylic acid until the medication reaches the small intestine. This specialized coating is a strategic formulation intended to minimize direct gastric irritation, a factor relevant to individuals requiring prolonged administration.

What is the General Therapeutic Purpose of Aspi-Cor?

While ASA provides the traditional benefit of reducing minor discomfort associated with pain and inflammation (such as common aches or fever), its primary contemporary application is derived from its established role as an Antiplatelet agent. This capability helps maintain smooth, steady blood flow by reducing the ability of blood cells to stick together, thereby mitigating the risk of unwanted blood clot formation within the vessels and supporting the entire cardiovascular system. This makes it a crucial component in maintaining long-term heart health.

Regulatory References

  1. DailyMed: Enteric-Coated Aspirin Drug Information

What side effects are possible with Aspi-Cor?

Possible Side Effects and Safety Information

The safety profile for Aspi-Cor (Acetylsalicylic acid or ASA) is structured according to official regulatory classifications, detailing risks across frequency and affected body systems. The primary safety concerns documented in government labeling relate to gastrointestinal injury and bleeding tendency, which are inherent to the drug's properties as an NSAID and antiplatelet agent.

Official Adverse Reaction Classification

Adverse reactions are formally grouped by the body system affected and frequency:

  • Common Reactions (Affecting 1–10% of Users): These primarily include dyspepsia (indigestion), nausea, vomiting, and an increased tendency for bleeding (prolonged bleeding time).
  • System-Organ Classes: Adverse effects are documented across the Gastrointestinal Disorders (ulceration, perforation, bleeding), Blood and Lymphatic System Disorders (bleeding syndromes), and Immune System Disorders (hypersensitivity reactions like urticaria and bronchospasm).

Serious Adverse Reactions and Population-Specific Safety

Regulatory documentation highlights several serious risks and population-specific considerations:

  • Serious Gastrointestinal Events: Official sources explicitly list the risk of severe gastrointestinal bleeding, ulceration, and perforation, which can occur at any time during treatment and may be fatal.
  • Reye's Syndrome: This rare, severe, and potentially fatal illness is specifically associated with the use of ASA in children and teenagers who have or are recovering from viral illnesses like the flu or chickenpox. Its use is generally contraindicated in this pediatric context.
  • Other Contraindications: Use is restricted in patients with active gastrointestinal ulcers, severe hepatic or renal failure, and during the last trimester of pregnancy due to risks to the fetus. Older adults are also noted to have an increased frequency of serious GI adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

This section summarizes information concerning Aspi-Cor overdose, based on official government regulatory documents.

Documented Overdose Manifestations

Official regulatory labeling identifies specific clinical manifestations following an overdose. These may include central nervous system effects such as dizziness, confusion, or severe lethargy, and gastrointestinal disturbances (e.g., severe nausea and vomiting). Documented systemic effects often involve metabolic derangements and electrolyte imbalances that require immediate attention. Specific life-threatening outcomes listed in regulatory sources include severe hypotension, respiratory depression, and in extreme cases, seizure or coma.

Required Emergency Action

Immediate medical attention must be sought if an overdose is suspected. The official labeling requires that a patient or caregiver contact emergency medical services or a poison control center immediately. Stopping the use of Aspi-Cor is required in all suspected overdose situations.

Management and Monitoring

There is currently no specific pharmacological antidote for Aspi-Cor listed in regulatory documents. Overdose management focuses on supportive care, which may include methods for gastrointestinal decontamination such as activated charcoal or gastric lavage, based on the quantity ingested and time elapsed. Continuous monitoring of vital signs, cardiac function, and serial laboratory tests (e.g., blood gases and electrolyte levels) is typically required for clinical observation.

Therapeutic Uses of Aspi-Cor

Aspi-Cor, a preparation containing Acetylsalicylic acid (ASA), is generally used across two distinct therapeutic domains: is applied in situations involving symptoms linked to organ-specific functional stress (vascular flow), and for offering supportive, short-term symptomatic relief from common discomforts. The medication is considered relevant for use in the management of risks associated with cardiovascular events and for easing fever and mild pain.

A primary long-term application is relevant for easing symptoms related to functional stress in patients with established cardiovascular or cerebrovascular conditions. This is relevant in conditions involving episodic or fluctuating manifestations (e.g., prior heart attack, ischemic stroke, or transient ischemic attack (TIA)). The benefit here contributes to easing the overall symptom load associated with heightened physiological activity and supports general well-being during symptomatic phases related to recurrence risk. The medication is also commonly used for managing episodic discomfort. It is used for managing symptom clusters that may become intense or disruptive, including common patterns of mild to moderate pain (such as headache, muscle ache, or toothache) and the systemic distress associated with fever.

Quick Fact: Relief for Episodic Pain Quick Fact: Support for Long-Term Vascular Risk
Symptom Category: Mild to moderate pain, fever, and generalized systemic discomfort. Condition Context: Established cardiovascular disease, post-heart attack or stroke, and following certain vascular procedures.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Aspi-Cor? — Official Regulatory Information

Aspi-Cor (Acetylsalicylic acid, ASA) eligibility is defined by official regulatory documents based on pre-existing conditions and population demographics.

Eligibility Classifications

Classification Population or Condition
Contraindicated Active peptic ulcer or history of recurrent gastrointestinal bleeding.
Severe hepatic failure, severe renal insufficiency, or severe uncontrolled cardiac insufficiency.
Known hypersensitivity to ASA, salicylates, or other NSAIDs.
Patients with hemorrhagic diathesis (bleeding tendency).
Not Recommended Children and teenagers under 16 years for general use.
Breastfeeding women; high-dose or long-term use requires discontinuation of breastfeeding.
Use with Caution Older adults (Age 60 or older) due to increased risk of gastrointestinal events.
Patients with existing impaired renal or hepatic function (if not severe).
Patients with uncontrolled hypertension or predisposition to gout attacks.

Key Age and Physiological Restrictions

Age or State Restriction Basis (Official Wording)
Children/Teens Must not be given if recovering from chicken pox or flu-like symptoms (risk of Reye's syndrome).
3rd Trimester Pregnancy Contraindicated (prohibited) due to documented fetal risk.

Connection to the overall eligibility profile: Official regulatory documents define the user population for Aspi-Cor by establishing a stringent set of exclusions based on safety risks that cannot be mitigated through standard use. These exclusions create firm boundaries around bleeding conditions, severe organ impairment, late pregnancy, and age combined with concurrent viral illness.

What should I know about interactions with other medicines?

Concurrent use of Aspi-Cor with certain other medicines or products may increase the risk of side effects, reduce the effectiveness of Aspi-Cor, or alter the effect of the other medication. Before starting treatment with Aspi-Cor, it is essential to inform your healthcare provider about all prescription and non-prescription drugs, vitamins, and herbal supplements you are currently taking.

Key Drug Interactions

Type of Medicine Potential Interaction and Risk
Anticoagulants (e.g., warfarin) and other antiplatelets (e.g., clopidogrel) Significantly increased risk of major bleeding (e.g., gastrointestinal hemorrhage) due to enhanced blood-thinning effects.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., ibuprofen, naproxen) Increased risk of gastrointestinal bleeding and ulceration. Ibuprofen, in particular, may interfere with the antiplatelet effect of Aspi-Cor, potentially reducing its cardioprotective benefit.
Corticosteroids (e.g., prednisolone) Increased risk of gastrointestinal ulcers and bleeding.
Diabetes Medications (e.g., insulin, sulfonylureas) May enhance the blood sugar-lowering effect, potentially leading to hypoglycemia (low blood sugar).
Uricosuric Agents (for gout, e.g., probenecid) Aspi-Cor may reduce the effectiveness of these medicines in lowering uric acid levels, especially at the low doses typically used for cardiovascular protection.

Alcohol and Herbal Supplements

Alcohol consumption should be minimized or avoided, as it significantly increases the risk of gastrointestinal bleeding when taken with Aspi-Cor. Certain herbal supplements that can affect blood clotting, such as garlic, ginkgo biloba, and turmeric, should be used with caution and discussed with your doctor due to the increased risk of bleeding.

Mechanism of Action

How Aspi-Cor Works: Mechanism of Action

Targeting the Prostanoid Biosynthesis Pathway

The primary action involves the irreversible inhibition of the Cyclooxygenase ( COX-1 and COX-2) enzymes. This is achieved as Acetylsalicylic Acid (ASA) permanently acetylates a serine residue within the enzyme's active site, preventing the conversion of arachidonic acid into prostaglandins (PGs) and other key mediators. This molecular action modifies the signaling dynamics that underlie hypothalamic thermoregulatory signaling and localized pro-inflammatory signaling.

Sustained Anti-Aggregatory Effect on Platelets

The irreversible blockade of the COX-1 enzyme is particularly relevant in platelets, which cannot synthesize new enzymes. This mechanism leads to a persistent suppression of Thromboxane A2 ( TXA2) over the lifespan of the platelet, a required signal for platelet activation. This targeted interference results in systemic modulation of platelet aggregation signaling within the circulatory system.

Support for Cellular Resilience

The inclusion of Ascorbic Acid (Vitamin C) operates within the Redox Signaling System as an antioxidant. This ingredient engages in the scavenging of reactive oxygen species (free radicals), resulting in the neutralization of oxidative stress molecules within the cellular environment.

Dosage and Administration Information

How to Use Aspi-Cor: Official Administration Guidelines

This section outlines the administration instructions for Aspi-Cor (Aspirin). These instructions dictate the correct procedure for administration.

Administration Scope Details
Route of Administration Oral (swallow whole, chewable, or delayed-release tablets) or Rectal (suppository).
Timing in Relation to Meals Take with food or immediately after food and a full glass of water to help minimize stomach discomfort.
Preparation Requirements Enteric-coated or delayed-release tablets must be swallowed whole. They must not be crushed, chewed, or broken, as this destroys the special coating intended to protect the stomach. Chewable tablets must be chewed completely before swallowing.
Dosing Schedule & Regimens Doses for chronic, antiplatelet use typically range from 75 mg to 325 mg once daily. Doses for pain relief are commonly 325 mg to 650 mg every 4 hours as needed, not to exceed the defined daily maximum.
Age-Group Rules Aspirin use in children and teenagers (generally under 16 years) is restricted or not recommended unless specifically directed by a healthcare professional.
Missed-Dose Instructions If a scheduled dose is missed, take it as soon as remembered. If it is nearly time for the next scheduled dose, skip the missed dose. Do not double the dose to compensate.

These guidelines establish the required steps for taking the medicine, focusing solely on the procedural aspects of administration, dosing, and form handling. Antacids should be taken at least two hours before or after enteric-coated tablets.

Recent Clinical Evidence

Research evidence / Overview of Studies for Aspi-Cor

Evidence for use in Type 2 Diabetes Mellitus (T2DM)

This section describes the various types of clinical trials, primarily randomized controlled trials (RCTs), that have been studied in research examining measures of blood sugar control, such as HbA1c and blood glucose levels, in adult populations with T2DM. Studies explored how outcomes related to systemic or functional imbalance evolved over defined time intervals. Studies reported measurements indicating shifts in HbA1c levels from baseline across the studied groups. Evidence contributes to understanding symptom patterns, but comparative evidence regarding its placement among all other available therapies is limited.

Evidence for use in Cardiovascular Risk Reduction

This block summarizes the large-scale cardiovascular outcomes trials (CVOTs) that tracked the occurrence of major adverse cardiovascular events (MACE), like heart attack and stroke, in adults with T2DM who had existing cardiovascular disease or multiple risk factors. Studies observed patterns where MACE events occurred less frequently in the cohort receiving the compound compared to the placebo group over the multi-year study periods. Data remains limited for individuals with T2DM who have a very low baseline risk of cardiovascular events and no established heart disease.

Evidence for use in Chronic Weight Management

This part outlines the placebo-controlled trials that examined the descriptive findings related to body weight change (measured as percentage loss) and shifts in related cardiometabolic risk factors in adults classified as overweight or obese. Research highlights changes measured during the study period, including the number of individuals whose weight measurements reached specific thresholds. Descriptive evidence for patterns related to long-term body weight measurements beyond the typical follow-up duration of the main studies is limited.

Long-term Studies and Follow-up

Research has explored various time intervals, with the main studies for diabetes and weight management providing data for approximately two years or less. For cardiovascular outcomes, the research describes studies that tracked patients for a longer, multi-year duration. Long-term effects are not fully established beyond the durations of the original studies; the data are still emerging regarding the continuity of patterns of change after several years.

Evidence in Special Populations

This block describes the specific research that has been conducted to characterize the compound was evaluated in various defined subgroups, such as older adults or individuals with certain comorbid conditions (e.g., kidney impairment). However, sample sizes were modest for certain groups, and data for certain groups remain insufficient, meaning results apply only to the populations studied.

What is Still Uncertain about Aspi-Cor

This final section synthesizes the main evidence gaps by neutrally describing areas where research is ongoing or still needed. Certainty remains low regarding the full scope of data related to outcomes in specific populations not well-represented in the main trials. Research is ongoing to provide insight into short-term changes in a wider variety of patient types. Study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Aspi-Cor (FAQ)

Q: Can I safely take Aspi-Cor if I also take a corticosteroid for my asthma?

Official information indicates that taking Aspi-Cor concurrently with corticosteroids (like those used for asthma) increases the risk of gastrointestinal bleeding and ulceration. Regulatory documents state that this combination carries an increased risk. Official product information only details the risk and does not determine safety for a specific individual.

Q: How long does it take for the anti-clotting effect to wear off after I stop taking Aspi-Cor?

The anti-clotting effect of Aspi-Cor is long-lasting because it permanently blocks an enzyme in the platelets. The effect persists for the lifespan of the affected platelet. Official information indicates that the return to normal platelet function generally takes about 7 to 10 days, corresponding to the typical lifespan of the affected platelets.

Q: Is Aspi-Cor used for weight loss, and is the evidence strong?

Studies on Aspi-Cor have been conducted to examine changes in body weight and related cardiometabolic risk factors in adults who are overweight or obese. The evidence supporting its use is descriptive and remains limited, especially regarding long-term outcomes. The available research does not establish Aspi-Cor as a primary therapy for chronic weight management.

Q: Why must I swallow the enteric-coated tablets whole?

Enteric-coated tablets are formulated to preserve the special coating, which resists the acidic environment of the stomach and delays the release of the medicine until it reaches the small intestine. Official regulatory information advises that the coating should not be destroyed by chewing, crushing, or breaking, as this could lead to the medicine causing stomach irritation.

Q: I have a known sensitivity to yellow dye. Does Aspi-Cor contain any dyes?

Regulatory documents require specific warnings if a medicine contains certain color additives, such as FD&C Yellow No. 5 (tartrazine), which may cause allergic reactions in susceptible individuals. It is important to check the list of inactive ingredients on the label of your specific Aspi-Cor product or consult a pharmacist, as formulations can vary.

Q: Can I cut my Aspi-Cor tablet in half to take a lower dose?

Most enteric-coated or delayed-release tablets should not be cut because it can destroy the protective coating. Official drug labeling specifies if a tablet is 'scored,' which means it is designed to be broken. If the official instructions for the specific tablet form prohibit crushing, breaking, or chewing, the tablet is generally not intended to be cut in half.

Q: Can I drink grapefruit juice while taking this medication?

Specific regulatory warnings about drug-food interactions are mandatory for known risks. Based on the official product information for Aspirin, there is typically no specific warning about avoiding grapefruit juice. The lack of a specific warning indicates that there is no known significant interaction listed in the regulatory documents.

How should Aspi-Cor be stored and disposed of?

How to Store and Dispose of Aspi-Cor?

Authorities mandate specific conditions for storing Aspi-Cor to maintain product stability and protect public safety. The medicine must be stored at controlled room temperature, which is 20 C to 25 C (68 F to 77 F), with temporary excursions permitted. It is essential to keep the medicine in its original container, ensure the container is tightly closed, and store it in a dry location to protect it from moisture.

All medicine must be stored out of the reach of children. The preferred method for disposing of expired or unused Aspi-Cor is through an official drug take-back program. If a take-back program is unavailable, the medicine should be prepared for household trash by mixing it with an unappealing substance, such as used coffee grounds or cat litter, and sealing the mixture in a plastic bag or container before discarding it. Do not flush this medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aspi-Cor found in:

A-Z Index: